Literature DB >> 26025388

SGLT inhibition and euglycaemic diabetic ketoacidosis.

Julia Hine1, Heather Paterson2, Esha Abrol2, David Russell-Jones2, Roselle Herring2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26025388     DOI： 10.1016/S2213-8587(15)00204-1

Source DB:  PubMed          Journal:  Lancet Diabetes Endocrinol        ISSN： 2213-8587            Impact factor:   32.069


× No keyword cloud information.
  22 in total

Review 1.  Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes.

Authors:  Taichi Nagahisa; Yoshifumi Saisho
Journal:  Diabetes Ther       Date:  2019-08-22       Impact factor: 2.945

Review 2.  Glycemic Management in the Operating Room: Screening, Monitoring, Oral Hypoglycemics, and Insulin Therapy.

Authors:  Elizabeth Duggan; York Chen
Journal:  Curr Diab Rep       Date:  2019-11-20       Impact factor: 4.810

3.  Downregulated miR-18a and miR-92a synergistically suppress non-small cell lung cancer via targeting Sprouty 4.

Authors:  Xinju Zhang; Xianyi Wang; Binshu Chai; Zong Wu; Xiaomin Liu; Heng Zou; Ziyi Hua; Zhongliang Ma; Weiwei Wang
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

4.  Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program.

Authors:  Ngozi Erondu; Mehul Desai; Kirk Ways; Gary Meininger
Journal:  Diabetes Care       Date:  2015-07-22       Impact factor: 19.112

5.  A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures.

Authors:  Charmi A Patel; Robert A Bailey; Ujjwala Vijapurkar; Gary Meininger; Lawrence Blonde
Journal:  BMC Health Serv Res       Date:  2016-08-05       Impact factor: 2.655

6.  Canagliflozin-Induced Diabetic Ketoacidosis: Case Report and Review of the Literature.

Authors:  Jessica Turner; Tahmina Begum; Roger D Smalligan
Journal:  J Investig Med High Impact Case Rep       Date:  2016-08-29

7.  Diabetic ketoacidosis in patients treated with SGLT2 inhibitors: experience at a tertiary hospital.

Authors:  Labrini Papanastasiou; Spyridoula Glycofridi; Christos Gravvanis; Nikitas Skarakis; Irene Papadimitriou; Georgia Kanti; Chara Kapsali; Theodora Kounadi
Journal:  Hormones (Athens)       Date:  2020-11-05       Impact factor: 2.885

8.  Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors.

Authors:  Wataru Ogawa; Kazuhiko Sakaguchi
Journal:  J Diabetes Investig       Date:  2015-09-06       Impact factor: 4.232

9.  Euglycemic Diabetic Ketoacidosis in a 27 year-old female patient with type-1-Diabetes treated with sodium-glucose cotransporter-2 (SGLT2) inhibitor Canagliflozin.

Authors:  Nimrah Bader; Lubna Mirza
Journal:  Pak J Med Sci       Date:  2016 May-Jun       Impact factor: 1.088

Review 10.  Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.

Authors:  James W Reed
Journal:  Vasc Health Risk Manag       Date:  2016-10-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.